U P Santosh, G B Ashwini, Chadha Baneet
Department of Otorhinolarngology, J J M Medical College, Davangere, Karnataka India.
Indian J Otolaryngol Head Neck Surg. 2023 Sep;75(3):2137-2141. doi: 10.1007/s12070-023-03818-x. Epub 2023 Apr 29.
Allergic rhinitis continues to pose a global burden in both adult and paediatric population and requires adequate medical therapy to avoid long term complications making it a challenging concern. This prompts the need to find a suitable and appropriate treatment regimen for this condition.
To study the clinical efficacy of Oral Bilastine and Probiotics in patients with allergic rhinitis. To compare the effectiveness of Bilastine monotherapy to Oral Bilastine combined with Probiotics in patients with allergic rhinitis.
Total of 100 patients were selected and randomized into two groups- Group 1 and Group 2 and were treated with Oral Bilastine 20 mg OD and Oral Bilastine 20 mg with Oral Probiotics OD (Lactobacillus fermentum & L. paracasei - 4 billion cells) respectively to maintain uniformity. Baseline scoring and follow up scoring after 6 weeks was done using the Total symptom score, Absolute eosinophil count and Nasal smear eosinophil count and were evaluated and documented as per their response to treatment.
A significant reduction was observed in the severity of symptoms especially nasal obstruction, sneezing in patients of both groups along with extra nasal symptoms, with average mean score in Group 1 being 7.72 before treatment that reduced to 3.66 and that of Group 2 from 9.32 to 5.02. The mean score of Group 2 was greater in both before and after treatment which is highly significant. (p < 0.001).
Monotherapy with Oral Bilastine has proven in relieving allergic symptoms. Addition of Oral Probiotics along with Bilastine has shown to have synergistic effect in further improving overall symptoms in allergic rhinitis.
过敏性鼻炎在成人和儿童群体中持续构成全球负担,需要适当的药物治疗以避免长期并发症,这使其成为一个具有挑战性的问题。这促使人们需要为这种疾病找到合适且恰当的治疗方案。
研究口服比拉斯汀和益生菌对过敏性鼻炎患者的临床疗效。比较比拉斯汀单药治疗与口服比拉斯汀联合益生菌治疗过敏性鼻炎患者的有效性。
共选取100例患者,随机分为两组——第1组和第2组,分别给予口服比拉斯汀20毫克每日一次和口服比拉斯汀20毫克加口服益生菌每日一次(发酵乳杆菌和副干酪乳杆菌——40亿个细胞)以保持一致性。在治疗6周后,使用总症状评分、绝对嗜酸性粒细胞计数和鼻涂片嗜酸性粒细胞计数进行基线评分和随访评分,并根据其对治疗的反应进行评估和记录。
两组患者的症状严重程度均有显著降低,尤其是鼻塞、打喷嚏以及鼻外症状,第1组治疗前平均评分为7.72,降至3.66,第2组从9.32降至5.02。第2组在治疗前后的平均评分均更高,差异具有高度显著性(p < 0.001)。
口服比拉斯汀单药治疗已被证明可缓解过敏症状。比拉斯汀联合口服益生菌已显示出在进一步改善过敏性鼻炎总体症状方面具有协同作用。